Ireland's Jazz Pharmaceuticals Q3 revenue beats; 2026 outlook lifted

Overview

• Ireland biopharma firm's Q3 revenue rose 10% yr/yr, beating analyst expectations

• Adjusted loss per share for Q3 came in below analyst expectations

• Q3 losses driven by $754 mln acquired R&D expense from Actio acquisition

Outlook

• Jazz raises 2026 total revenue guidance to $4.775-$4.85 bln

• Company expects 2026 GAAP effective tax rate of 20%-30%

• Jazz maintains 2026 GAAP gross margin of 89%-90%

Result Drivers

• XYWAV GROWTH - Higher Xywav sales and new patient additions drove revenue growth

• ZEPZELCA UPTAKE - Increased use of Zepzelca and atezolizumab combination in 1L maintenance small-cell lung cancer supported revenue

• ZIIHERA LAUNCH - Early demand for newly launched Ziihera in HER2+ 1L gastroesophageal adenocarcinoma contributed to revenue

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $300.00, about 38.9% above its October 30 closing price of $215.98

• The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

Reuters Recommended Reads

• Nov 2 - Dr Reddy's gets tentative US FDA nod for generic HIV prevention

• Nov 2 - Bavarian Nordic gets four-year contract for mpox and smallpox vaccine from UK government

• Nov 2 - Deutsche Bank upgrades US tech, says selloff has gone too far

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)